GBA1 and drug-induced dyskinesia: Avenali et al. examined long-term outcomes in a large Italian cohort, showing that GBA mutation carriers (GBA-PD) experience significant motor improvement and reduced motor fluctuations, dyskinesias, and impulsive-compulsive disorders post-DBS.